|
Arie Belldegrun M.D. FACS has served on Hana's Board of Directors since April 2004. He has served as Professor of Urology since 1994 Chief of the Division of Urologic Oncology since 1996 at the David Geffen School of Medicine at the University of California Los Angeles (UCLA). He has also held the Roy and Carol Doumani Chair in Urologic Oncology at UCLA since 2000. Dr. Belldegrun completed his medical degree at the Hebrew University Hadassah Medical School in Jerusalem his post at the Weizmann Institute of Science and his residency in Urology at Harvard Medical School. Prior to UCLA Dr. Belldegrun served as a research fellow in surgical oncology at the National Cancer Institute/NIH under Steven A. Rosenberg MD Ph.D. from 1985 to 1988. He is certified by the American Board of Urology and is a Fellow of the American College of Surgeons. Dr. Belldegrun is on the scientific boards of several biotechnology and pharmaceutical companies and serves as a reviewer for many medical journals and granting organizations. In addition to holding several patents Dr. Belldegrun is the author of several books on prostate and kidney cancers and has written over 350 scientific publications with an emphasis on urologic oncology particularly kidney prostate and bladder cancers. He is the founder of Agensys Inc. a company focused on the development of fully human monoclonal antibodies to treat solid tumor cancers based on Agensys' propriety targets. Dr. Belldegrun served as founding Chairman of Agensys from 1997-2002 and currently serves on the Board of Directors and as a consultant. Dr. Belldegrun is also Vice Chairman of the Board of Directors and Chairman of the Scientific Advisory Board of Cougar Biotechnology Inc. established to in-license and develop early clinical stage drugs with a specific focus on the field of oncology. | 